Portage Biotech Inc. (NASDAQ:PRTG – Get Rating) – Research analysts at Oppenheimer boosted their Q2 2023 EPS estimates for Portage Biotech in a research note issued to investors on Wednesday, September 14th. Oppenheimer analyst M. Biegler now expects that the company will post earnings of ($0.26) per share for the quarter, up from their prior estimate of ($0.28). Oppenheimer currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for Portage Biotech’s current full-year earnings is ($0.95) per share. Oppenheimer also issued estimates for Portage Biotech’s Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at ($0.28) EPS, FY2023 earnings at ($0.96) EPS and FY2024 earnings at ($1.27) EPS.
Portage Biotech Trading Down 3.2 %
Portage Biotech stock opened at $7.60 on Monday. Portage Biotech has a 1 year low of $4.62 and a 1 year high of $23.99. The company has a market cap of $128.78 million, a PE ratio of -6.55 and a beta of 1.81. The company’s 50-day moving average is $8.66 and its two-hundred day moving average is $7.84.
Institutional Trading of Portage Biotech
A number of large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC bought a new position in Portage Biotech during the 1st quarter worth $53,000. Sigma Planning Corp bought a new position in Portage Biotech in the first quarter valued at about $75,000. Goldman Sachs Group Inc. acquired a new stake in shares of Portage Biotech during the second quarter valued at about $79,000. Beacon Investment Advisory Services Inc. acquired a new position in shares of Portage Biotech in the second quarter worth approximately $80,000. Finally, Millennium Management LLC acquired a new position in shares of Portage Biotech in the second quarter worth approximately $92,000. 0.97% of the stock is owned by institutional investors.
About Portage Biotech
Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury.
- Get a free copy of the StockNews.com research report on Portage Biotech (PRTG)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.